The Oxford Science Park

Find Out The Latest

Keep in touch with news and developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn

Wireless innovator CableFree celebrates 30 years at The Oxford Science Park

31 Mar 2026

CableFree marked a major milestone recently as it celebrated its 30th anniversary. Since its founding in 1996, CableFree has been based at The Oxford Science Park, where it has grown from a small team of visionary engineers into a global provider of 4G, 5G, microwave, millimetre‑wave and Free Space Optics solutions installed in over 90 countries. Over three decades, the company has powered networks across industries including telecoms,... Read more

The Oxford Science Park team runs for children’s hospital

31 Mar 2026

A team of 30 runners from across The Oxford Science Park came together last month to take part in the annual OX5 Run at Blenheim Palace, raising an impressive £2,851 for the Oxford Children’s Hospital and children’s services within the Oxford University Hospitals NHS Foundation Trust. Representing a wide range of organisations based at the Park, participants included colleagues from Sitryx, Bond Williams, Enara Bio, Orthoson, the Ellison... Read more

Constantin Coussios appointed Pro-Vice-Chancellor for Innovation

30 Mar 2026

The Oxford Science Park (TOSP) warmly congratulates Professor Constantin Coussios on his appointment as Pro-Vice-Chancellor for Innovation at the University of Oxford, a role he will take up at the end of April 2026. A pioneer in biomedical engineering and a driving force behind some of Oxford’s most successful spinouts, Professor Coussios has long been embedded in the innovation community that thrives at the Park. His appointment marks a... Read more

Evox Therapeutics enters partnership to evaluate new gene editing technology for Rett Syndrome

27 Feb 2026

Evox Therapeutics, a biotechnology company developing innovative therapies for genetically driven neurodegenerative diseases using a next-generation gene editing modality, has announced it is initiating a collaboration with the Rett Syndrome Research Trust (RSRT) to assess the feasibility of using the company’s ExoEdit® exosome-based delivery platform to enable the development of a gene editing treatment for Rett syndrome. Rett syndrome is a... Read more

Boehringer Ingelheim licenses novel oral therapeutics program from Sitryx Therapeutics